These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32871648)

  • 1. Relationship between growth velocity and change of levels of insulin-like growth factor-1, insulin-like growth factor binding protein-3 and, IGFBP-3 promoter polymorphism during GnRH agonist treatment.
    Park JH; Hwang IT; Yang S
    Ann Pediatr Endocrinol Metab; 2020 Dec; 25(4):234-239. PubMed ID: 32871648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between serum insulin-like growth factor-1, IGF binding protein-3 levels and body height before and after gonadotropin-releasing hormone agonist therapy.
    Song HS; Choi WB; Song JS; Hwang IT; Yang S
    Ann Pediatr Endocrinol Metab; 2014 Dec; 19(4):208-13. PubMed ID: 25654067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The acid-labile subunit of human ternary insulin-like growth factor-binding protein complex in girls with central precocious puberty before and during gonadotropin-releasing hormone analog therapy.
    Cisternino M; Draghi M; Lauriola S; Scarcella D; Bernasconi S; Cavallo L; De Luca F; Lomeo A; Tatò L
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4629-33. PubMed ID: 12364447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irreversible increase of serum IGF-1 and IGFBP-3 levels in GnRH-dependent precocious puberty of different etiologies: implications for the onset of puberty.
    Belgorosky A; Rivarola MA
    Horm Res; 1998; 49(5):226-32. PubMed ID: 9568807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like Growth Factor 1, but Not Insulin-Like Growth Factor-Binding Protein 3, Predicts Central Precocious Puberty in Girls 6-8 Years Old: A Retrospective Study.
    Escagedo PD; Deal CL; Dwyer AA; Hauschild M
    Horm Res Paediatr; 2021; 94(1-2):44-51. PubMed ID: 34098553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-I and IGF binding protein-3 remain high after GnRH analogue therapy in girls with central precocious puberty.
    Kanety H; Karasik A; Pariente C; Kauschansky A
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):7-12. PubMed ID: 8796132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of type I procollagen C-terminal propeptide, insulin-like growth factor-I (IGF-I), and IGF binding protein-3 in obese children and adolescents: relationship to gender, pubertal development, growth, insulin, and nutritional status.
    Falorni A; Bini V; Cabiati G; Papi F; Arzano S; Celi F; Sanasi M
    Metabolism; 1997 Aug; 46(8):862-71. PubMed ID: 9258266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
    Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
    Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations among IGF-1, IGF2, IGF-1R, IGF-2R, IGFBP-3, insulin genetic polymorphisms and central precocious puberty in girls.
    Chang HP; Yang SF; Wang SL; Su PH
    BMC Endocr Disord; 2018 Sep; 18(1):66. PubMed ID: 30249230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced levels of GH during GnRH analogue treatment in pubertal short girls born small for gestational age (SGA).
    van der Kaay DC; Rose SR; van Dijk M; Noordam C; van Rheenen E; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2009 Jun; 70(6):914-9. PubMed ID: 19178519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overnight levels of luteinizing hormone, follicle-stimulating hormone and growth hormone before and during gonadotropin-releasing hormone analogue treatment in short boys born small for gestational age.
    van der Kaay DC; de Jong FH; Rose SR; Odink RJ; Bakker-van Waarde WM; Sulkers EJ; Hokken-Koelega AC
    Horm Res; 2009; 71(5):260-7. PubMed ID: 19339790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The alteration of IGF-1 levels and relationship between IGF-1 levels and growth velocity during GnRH analogue therapy.
    Muratoglu Sahin N; Peltek Kendirci HN; Çetinkaya S; Savaş Erdeve Ş; Aycan Z
    J Pediatr Endocrinol Metab; 2020 Jan; 33(1):113-120. PubMed ID: 31809263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin releasing hormone agonist treatment to increase final stature in children with precocious puberty: a meta-analysis.
    Li P; Li Y; Yang CL
    Medicine (Baltimore); 2014 Dec; 93(27):e260. PubMed ID: 25501098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth.
    Tillmann V; Patel L; Gill MS; Whatmore AJ; Price DA; Kibirige MS; Wales JK; Clayton PE
    Clin Endocrinol (Oxf); 2000 Sep; 53(3):329-36. PubMed ID: 10971450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing adult height gain and menarcheal age between girls with central precocious puberty treated with gonadotropin-releasing hormone agonist alone and those treated with combined growth hormone therapy.
    Kim MS; Koh HJ; Lee GY; Kang DH; Kim SY
    Ann Pediatr Endocrinol Metab; 2019 Jun; 24(2):116-123. PubMed ID: 31261476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of peripubertal children after renal transplantation (RTX) with recombinant human growth hormone: auxological data and effects on insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) during 24 months.
    Riedl S; Lebl J; Kluge M; Kreisinger J; Simková E; Kohlhauser C; Balzar E; Frisch H
    J Pediatr Endocrinol Metab; 1998; 11(6):713-8. PubMed ID: 9829225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone.
    Jung MK; Song KC; Kwon AR; Chae HW; Kim DH; Kim HS
    Ann Pediatr Endocrinol Metab; 2014 Dec; 19(4):214-9. PubMed ID: 25654068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins -1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty.
    Juul A; Flyvbjerg A; Frystyk J; Müller J; Skakkebaek NE
    Clin Endocrinol (Oxf); 1996 May; 44(5):515-23. PubMed ID: 8762727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.